The reported statements, read against the company's own industry.
Financials view
Market Capitalization
152.99MUSD
183.02M · vs all stocks (USD)
Updated Oct 19, 2026
Revenue (TTM)
11.86MUSD
14.48M · vs all stocks (USD)
Updated Oct 19, 2026
Profit Margin
-170.10%
vs Biotechnology peers
Updated Oct 19, 2026
Beta
0.0940x
vs all stocks
Updated Oct 19, 2026
52-Week Change
-39.82%
vs all stocks
Updated Oct 19, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 19, 2026
Market Capitalization
152.99MUSD
183.02M · vs all stocks (USD)
Updated Oct 19, 2026
Enterprise Value
126.25MUSD
142.04M · vs all stocks (USD)
Updated Oct 19, 2026
Forward P/E
-5.17x
vs Biotechnology peers
Updated Oct 19, 2026
Price to Sales (TTM)
12.90x
vs Biotechnology peers
Updated Oct 19, 2026
Price to Book (MRQ)
4.29x
vs Biotechnology peers
Updated Oct 19, 2026
Enterprise to Revenue
10.64x
vs Biotechnology peers
Updated Oct 19, 2026
Enterprise to EBITDA
-4.11x
vs Biotechnology peers
Updated Oct 19, 2026
Gross Margin
10.90%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 15.46%.Updated Oct 19, 2026
Profit Margin
-170.10%
vs Biotechnology peers
Updated Oct 19, 2026
Operating Margin
-305.89%
vs Biotechnology peers
Updated Oct 19, 2026
Return on Assets (TTM)
-28.59%
vs Biotechnology peers
Updated Oct 19, 2026
Return on Equity (TTM)
-72.37%
vs Biotechnology peers
Updated Oct 19, 2026
Revenue (TTM)
11.86MUSD
14.48M · vs all stocks (USD)
Updated Oct 19, 2026
Revenue per Share (TTM)
0.9570USDUpdated Oct 19, 2026
Quarterly Revenue Growth
-45.80%
vs Biotechnology peers
Updated Oct 19, 2026
Gross Profit (TTM)
1.83MUSD
2.84M · vs all stocks (USD)
Updated Oct 19, 2026
EBITDA (TTM)
-30.75MUSD
-27.02M · vs all stocks (USD)
Updated Oct 19, 2026
Net Income (TTM)
-20.18MUSD
-26.11M · vs all stocks (USD)
Updated Oct 19, 2026
Operating Cash Flow (TTM)
-22.14MUSD
-18.77M · vs all stocks (USD)
Updated Oct 19, 2026
Levered Free Cash Flow (TTM)
-29.05MUSD
-18.44M · vs all stocks (USD)
Updated Oct 19, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 19, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Oct 19, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 19, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 19, 2026
Revenue
16.96MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
13.71MUSDFY2025 · Dec 31, 2025
Gross Profit
3.25MUSDFY2025 · Dec 31, 2025
Operating Income
-25.28MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-23.71MUSDFY2025 · Dec 31, 2025
Income Tax Expense
169.00KUSDFY2025 · Dec 31, 2025
Net Income
-23.88MUSDFY2025 · Dec 31, 2025
EBIT
-23.33MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-22.21MUSDFY2025 · Dec 31, 2025
Research & Development
14.32MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
13.93MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
1.86MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
380.00KUSDFY2025 · Dec 31, 2025
EPS (Basic)
-2.10USDFY2025 · Dec 31, 2025
EPS (Diluted)
-2.10USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
11.38MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
11.38MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-23.88MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-12.85MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-18.35MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
4.80MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-23.88MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
1.86MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
3.11MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
201.00KUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
4.88MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
2.35MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-1.36MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-5.50MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-5.50MUSDFY2025 · Dec 31, 2025
Other Financing Charges
-1.43MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
25.99MUSDFY2025 · Dec 31, 2025
Shares Outstanding
12.91MSharesUpdated Oct 19, 2026
Float Shares
8.87MSharesUpdated Oct 19, 2026
Shares Short
1.84MSharesUpdated Oct 19, 2026
Short Ratio
18.61days
vs all stocks
Updated Oct 19, 2026
Short % of Shares Outstanding
16.32%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 14.29%.Updated Oct 19, 2026
% Held by Insiders
16.71%
vs all stocks
Updated Oct 19, 2026
% Held by Institutions
55.94%
vs all stocks
Updated Oct 19, 2026
Total Cash (MRQ)
35.34MUSD
44.65M · vs all stocks (USD)
Updated Oct 19, 2026
Total Cash per Share (MRQ)
2.74USDUpdated Oct 19, 2026
Total Debt (MRQ)
8.61MUSD
8.13M · vs all stocks (USD)
Updated Oct 19, 2026
Total Debt to Equity (MRQ)
0.2414x
vs Biotechnology peers
Updated Oct 19, 2026
Current Ratio (MRQ)
2.32x
vs Biotechnology peers
Updated Oct 19, 2026
Book Value per Share (MRQ)
2.76USDUpdated Oct 19, 2026
Total Assets
86.25MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
59.96MUSDFY2025 · Dec 31, 2025
Total Liabilities
42.62MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
26.29MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
16.91MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
25.71MUSDFY2025 · Dec 31, 2025
Cash
4.80MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
4.80MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
48.34MUSDFY2025 · Dec 31, 2025
Accounts Receivable
1.62MUSDFY2025 · Dec 31, 2025
Inventory
4.09MUSDFY2025 · Dec 31, 2025
Accounts Payable
3.61MUSDFY2025 · Dec 31, 2025
Deferred Revenue
1.18MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
13.53MUSDFY2025 · Dec 31, 2025
Long-term Debt
8.15MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
8.29MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
258.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-228.93MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
43.63MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
11.84USDUpdated Oct 19, 2026
52-Week High
20.03USDUpdated Oct 19, 2026
52-Week Change
-39.82%
vs all stocks
Updated Oct 19, 2026
Beta
0.0940x
vs all stocks
Updated Oct 19, 2026
50-Day MA
13.27USDUpdated Oct 19, 2026
200-Day MA
15.51USDUpdated Oct 19, 2026
Avg 10-Day Volume
74.25KSharesUpdated Oct 19, 2026
Avg 30-Day Volume
86.06KSharesUpdated Oct 19, 2026
Diluted EPS (TTM)
-2.17USDUpdated Oct 19, 2026
Other Income / Expense
753.00KUSDFY2025 · Dec 31, 2025
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.41Altman Z-Score: -1.78
Financial Health
Altman Z-Score -1.78: distress zoneCritical
Altman Z-Score: -1.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $183.02M, lower than 95% of all stocks globallySignificant
Market cap (USD): 183,016,111Global P5: 273,689,256.68
Revenue is $14.48M, lower than 95% of all stocks globallySignificant